Investors & Partners
A Platform Designed to Turn One Scaffold into Multiple Oncology Programs
VestraNova is developing a reusable antibody scaffold architecture intended to reduce immune-related development risk upstream and support multiple downstream therapeutic programs.
Investment Thesis
The Investment Thesis
Most therapeutic development absorbs risk one program at a time. VestraNova is pursuing a different model: engineer the scaffold once, validate it rigorously, and extend that architecture across multiple programs.
If successful, this approach may enable:
- Shared risk reduction across assets
- More efficient pipeline expansion
- Multiple partnership pathways from a common foundation
Platform Economics
Why Platform Economics Matter
In traditional development models, each program carries its own technical risk. In a scaffold-based model, foundational validation may carry across the broader portfolio. Our goal is to demonstrate that scaffold-level engineering can function as a reusable design principle rather than a single-asset feature.
Oncology Targets
Development Pipeline
A single deimmunized scaffold designed to address high-value oncology targets across 8 therapeutic areas and 7 modality formats.
| Therapeutic Area | Targets | Modality | Status |
|---|---|---|---|
| Breast Cancer | HER2, Trop-2, Nectin-4 | ADC, BiTE | Lead Program |
| Lung Cancer | EGFR, HER3, MET, DLL3 | ADC, BiTE | Profiled |
| Gastric / GI | Claudin 18.2, HER2, GPC3 | ADC | Profiled |
| Hematologic | CD19, CD22, BCMA, CD33 | ADC, CAR-T, BiTE | Profiled |
| Urothelial | Nectin-4, EpCAM | ADC | Profiled |
| Gynecologic | FRα, Mesothelin | ADC | Profiled |
| Prostate | PSMA | RIT, ADC | Profiled |
| Multi-Tumor | B7-H3, CEACAM5, EGFR | ADC, BiTE | Profiled |
Next Milestone
Next Value Inflection: Scaffold De-Immunization Validation
The next major milestone is wet-lab confirmation of scaffold de-immunization using human immune-cell assays, including PBMC testing. This is the highest-leverage near-term experiment in the company.
Tests the Platform Hypothesis
Directly validates the core scientific thesis that scaffold-level engineering can reduce immune recognition.
Supports the Scaffold
Results apply to the shared foundation, not only one individual program or therapeutic candidate.
Strengthens the Portfolio
May strengthen confidence across the broader pipeline built on the same engineered scaffold.
One validation event may inform every program built on the scaffold.
Status
Development Status
The company has established its computational platform foundation and is progressing toward targeted experimental validation.
- Engineered scaffold architecture established
- Computational profiling across multiple oncology targets
- Platform and program-level IP development underway
- Wet-lab validation defined as the next milestone
Patient Impact
What This Means for Patient Care
If scaffold-level engineering reduces immune-related liabilities as intended, the implications extend beyond development efficiency alone.
Better Tolerability
Reducing immune recognition at the scaffold level may lower the risk of anti-drug antibody responses, supporting therapies that are better tolerated over time.
More Consistent Dosing
By addressing immunogenicity upstream, treatments may maintain more consistent pharmacokinetics, reducing the need for dose adjustments or immunosuppressive co-therapies.
Sustained Treatment Duration
Therapies built on a deimmunized scaffold may support longer treatment courses before immune-mediated clearance limits continued use.
Partnerships
Partnership Strategy
The platform is designed to support multiple strategic paths. Because the architecture is reusable, value is not confined to a single asset.
Target-Specific Partnerships
Collaborations focused on individual oncology targets within the platform portfolio.
Platform Collaborations
Broader partnerships leveraging the full scaffold architecture across multiple programs.
Licensing Opportunities
Licensing tied to scaffold-enabled programs across targets and modalities.
Timing
Why Now
VestraNova is transitioning from computational platform construction to experimental validation. This stage is critical, as it converts a design thesis into data that can be evaluated through diligence and partnership discussions.
Start the Conversation
We welcome inquiries from investors, strategic partners, and collaborators aligned with our approach to antibody therapeutic development.